Changchun High-Tech Industry (Group) (000661) investor relations material

Executive summary

• Revenue for 2025 was ¥12.08 billion, down 10.27% year-over-year; net profit attributable to shareholders was ¥155 million, a 94% decrease year-over-year.

• Major subsidiaries saw mixed results: core pharma subsidiary revenue fell 7.98% and net profit dropped 81.83%; vaccine subsidiary revenue fell 50.77% with a net loss; TCM subsidiary revenue was stable.

• R&D investment increased 9.16% to ¥2.94 billion, representing 24.3% of revenue; 38 key products entered clinical stages.

• Adjustments in product pricing and sales policy, especially after inclusion of key products in the national reimbursement list, impacted revenue and profit.

Financial highlights

• Operating cash flow was ¥802 million, down 74.16% year-over-year.

• Basic and diluted EPS were both ¥0.39, down 93.93% year-over-year.

• Gross margin for biopharma products remained high at 89.16%.

• Total assets at year-end were ¥30.08 billion, down 3.13% from the previous year.

• Net assets attributable to shareholders were ¥22.01 billion, down 4.31% year-over-year.

Outlook and guidance

• Focus on innovation-driven growth, international expansion, and product pipeline advancement.

• Plans to strengthen core pharma business, accelerate commercialization of new products, and optimize asset allocation.

• Continued high R&D investment and global licensing deals expected to support long-term growth.